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Lgl1 controls NG2 endocytic pathway to regulate
oligodendrocyte differentiation and asymmetric cell
division and gliomagenesis
Mathieu Daynac1, Malek Chouchane1, Hannah Y. Collins1,8, Nicole E. Murphy1, Noemi Andor 1,9, Jianqin Niu2,
Stephen P.J. Fancy2,3, William B. Stallcup4 & Claudia K. Petritsch 1,5,6,7
Oligodendrocyte progenitor cells (OPC) undergo asymmetric cell division (ACD) to generate
one OPC and one differentiating oligodendrocyte (OL) progeny. Loss of pro-mitotic pro-
teoglycan and OPC marker NG2 in the OL progeny is the earliest immunophenotypic change
of unknown mechanism that indicates differentiation commitment. Here, we report that
expression of the mouse homolog of Drosophila tumor suppressor Lethal giant larvae 1 (Lgl1)
is induced during OL differentiation. Lgl1 conditional knockout OPC progeny retain NG2 and
show reduced OL differentiation, while undergoing more symmetric self-renewing divisions at
the expense of asymmetric divisions. Moreover, Lgl1 and hemizygous Ink4a/Arf knockouts in
OPC synergistically induce gliomagenesis. Time lapse and total internal reflection microscopy
reveals a critical role for Lgl1 in NG2 endocytic routing and links aberrant NG2 recycling to
failed differentiation. These data establish Lgl1 as a suppressor of gliomagenesis and positive
regulator of asymmetric division and differentiation in the healthy and demyelinated
murine brain.
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Adult oligodendrocyte progenitor cells (OPC) expressingthe proteoglycan NG2 (CSPG4) continuously divide andgenerate differentiating oligodendrocytes (OL) through-
out adulthood1. OPC divisions are frequently asymmetric and
generate progeny of distinct fate, where only one of the daughter
cells preserves NG2 expression and the opposite daughter cell
downregulates NG22,3. Thus far, asymmetric distribution of NG2
protein is the earliest immunophenotypic change amongst
daughter cell pairs generated by asymmetric cell division (ACD).
NG2-positive daughter cells proliferate at higher rates than NG2-
negative cells, showing that the early phenotypic asymmetry
correlates with distinct short-term fate2. NG2 contributes to
establishing this cell fate bias within newly generated cell pairs
after ACD. NG2 binds platelet-derived growth factor-AA (PDGF-
AA) and PDGF receptor alpha (PDGFRα) and thereby enhances
PDGFRα signaling and promotes timely OPC proliferation4–7.
Moreover, long-term fate tracking of the ACD progeny showed
that early NG2 asymmetry permanently affects cell fate. The
NG2-positive progeny of ACD retain OPC characteristics while
the NG2-negative progeny upregulate CC1, a marker for com-
mitment to the OL fate, and eventually differentiate2,8,9. Impor-
tantly, chemical-induced demyelination increases the rates of
NG2 asymmetry9. Collectively, the data underline that asym-
metric distribution of NG2 marks and also actively generates
different OPC progeny. Furthermore, ACD balances OPC pro-
liferation with differentiation in the normal brain and generates
OL in demyelinated lesions to contribute to remyelination2,3,9,10.
It is unclear how the downregulation of NG2 protein is achieved
in the differentiating oligodendrocyte. This lack of mechanistic
insights into ACD and early differentiation limits our under-
standing of brain homeostasis.
OPC give rise to glioma in genetically engineered mouse
models11–14. When undergoing neoplastic transformation, OPC
show higher rates of symmetric self-renewing divisions at the
expense of ACD2. These data suggest that downregulation of
NG2 in OPC progeny is critical for ACD, differentiation, and
attenuation of tumorigenesis2.
Surface levels of the membrane-spanning NG2 protein are
regulated by clathrin-mediated endocytosis in mouse embryonic
fibroblasts15. Clathrin-mediated or receptor-mediated endocy-
tosis is a multi-step process, whereby membrane-localized pro-
teins are engulfed as cargo in clathrin-coated pits, which then bud
off the membrane to form the early endosome. Cargo proteins are
then sorted into either the recycling endosome and re-integrated
into the membrane or targeted to the late endosome and subse-
quently the lysosome for degradation16. It is not known whether
NG2 trafficking by the endocytic pathway is important for NG2
downregulation and OL differentiation.
The WD40 repeat-containing protein lethal giant larvae (Lgl)
was initially characterized as a tumor suppressor gene, in Dro-
sophila melanogaster17, and it was subsequently shown to mediate
ACD of Drosophila neuroblasts18. Lgl is an evolutionary con-
served protein that initiates cell polarity by recruiting proteins to
membrane subdomains (for review, see ref. 19). As one of two
mammalian Lgl genes20, Lgl1 is highly expressed in the brain21.
Lgl1 knockout studies during mouse embryogenesis have revealed
a function for Lgl1 in polarity and adherens junction integrity in
neuroepithelial cells22, and in suppressing proliferation of dorsal
telencephalon radial glial progenitors at early postnatal stages23.
A bona-fide tumor suppressor role for Lgl1 in gliomagenesis is
supported by studies showing that loss of tumor suppressor
PTEN, a frequent and early driver mutation in glioblastoma24,
inhibits Lgl1 activity25. Constitutively active Lgl1 inhibits inva-
sion and induces differentiation of primary human glioblastoma
cells26. Nevertheless, a tumor suppressive role for Lgl1 in OPC
has not been investigated yet.
Here, we report that Lgl1 expression is upregulated during OL
differentiation and that Lgl1 protein is detected in committed OL
in the adult murine brain. Lgl1 conditional knockout (cKO) OPC
show a differentiation defect characterized by an aberrant co-
expression of NG2 with OL commitment markers. Moreover, in
Lgl1 cKO OPC rates of ACD are reduced while rates of sym-
metric, self-renewing divisions and proliferation are increased, in
both intact and chemically demyelinated corpus callosum (CC).
Lgl1 knockout synergizes with hemizygous Ink4a/Arf knockout in
OPC to induce gliomagenesis. Time lapse imaging of surface-
labeled, endocytosed NG2 shows decreased co-localization with
the lysosome in Lgl1 cKO OPC. Additionally, total internal
reflection microscopy reveals that in Lgl1 cKO OPC NG2
bypasses degradation and is rather recycled to the membrane.
Aberrant NG2 recycling is linked to defective OPC differentiation.
Thus, we establish Lgl1 as a positive regulator of differentiation
and ACD and suppressor of gliomagenesis. We suggest that Lgl1
promotes differentiation by supporting NG2 routing to the
lysosome.
Results
Lgl1 expression is upregulated in OL differentiation. To
unravel the mechanism for NG2 down-regulation, we searched
the RNA-Seq transcriptome database27 for conserved ACD reg-
ulator genes with altered expression in OL versus OPC. We
noticed a four-fold increase of Lgl1 (Llgl1) transcript in newly
formed OL versus OPC, suggesting that Llgl1 expression is
increased upon OL differentiation. To directly test this notion,
OPC were isolated from the white matter area of the CC of
postnatal days 30–60 (P30–P60) mice and cultured in parallel
under proliferation and differentiation conditions (Fig. 1a). We
performed immunofluorescence staining for OPC marker NG2
and mature OL marker O4 to show differentiation. As expected,
we found O4-expressing cells displaying a branched OL mor-
phology only under differentiation but not under proliferation
conditions (Fig. 1b). We used quantitative real-time PCR (qrt-
PCR) to assess changes in Llgl1 transcript levels with differ-
entiation and aging. Analyses reveal a significant increase in Llgl1
transcript under differentiation conditions (2.5-fold, p < 0.01)
(Fig. 1c), along with differentiation markers Mbp, Slc1a1, Ndrg1,
GPR17, and Mog. We noted that OPC markers, such as Cspg4
(NG2), Olig2, and Sox10 are unchanged. Llgl1 transcript levels
increase with age, being higher at P60 in OPC, and reaching a
peak at P180 in OL (Supplementary Figs. 1d, e).
To test whether Lgl1 protein expression is detectable in
differentiated OL in situ, as suggested by our transcript analyses,
we co-immunostained P35 wildtype mouse brain sections for
Lgl1, OPC markers PDGFRα, and NG2 (Fig. 1d, Supplementary
Fig. 1a), and committed OL marker CC1 (Fig. 1e)8. A
quantification of all detectable Lgl1-positive cells in the CC
revealed that more Lgl1-expressing cells are CC1 positive (59%)
than PDGFRα (14%) and NG2 (22%) positive, respectively
(Fig. 1f, g). Expression of Lgl1 is undetectable in NG2-positive
OPC in the subventricular zone (Supplementary Figs. 1b, c).
Hence, Lgl1 expression increases with differentiation and
overlaps largely with differentiating OL, suggesting therefore its
potential role in a differentiation mechanism.
Lgl1 knockout in OPC blocks OL differentiation. The expres-
sion pattern suggests that Lgl1 positively regulates OL differ-
entiation. In order to investigate a putative role for Lgl1 in OPC
differentiation, we used a mouse model where Lgl1 knockout is
targeted to NG2 cells28. We bred NG2-CreERT2 driver mice9 with
red-fluorescence protein Cre-reporter (Ai14-Tom)29 and Lgl1
floxed (Lgl1fl/fl)21,23 mice, as well as Lgl1 wildtype (Lgl1wt/wt) mice
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as controls. Compound transgenic mice were injected with
tamoxifen once at P30 and recombined cells were identified by
immunofluorescence staining for red fluorescent protein dTo-
mato (aka Tom+ cells) (Fig. 2a). NG2 and CC1 co-staining
(Fig. 2b) revealed that amongst Tom+ cells, NG2+ CC1+ cells
were increased (WT= 14.7% vs. cKO= 30.3%; p < 0.01), CC1+
cells were decreased (WT= 51.8% vs. cKO= 37.6%; p < 0.01)
and NG2+ cells were not significantly changed in Lgl1 cKO vs.
Lgl1 WT CC (Fig. 2c). These data show that Lgl1 is not required
for CC1 expression in OPC progeny. Lgl1 is rather required
for NG2 protein down-regulation and positively regulates OL
differentiation.
To provide further evidence that Lgl1 positively regulates
OL differentiation, we analyzed ex vivo isolated Lgl1 cKO cells
(Fig. 2d) for expression of OL maturation marker O4 and OPC
marker PDGFRα at P60 (Figs. 2e, f, Supplementary Figs. 2a, b)
and at P120 (Supplementary Figs. 2c, d). Indeed, we find that
the total number of OPC increased to a greater extent than OL
(OPC= 4.5 fold cKO vs. WT; p= 0.002; OL= 2.3 fold cKO vs.
WT; p= 0.06) at P60 (Fig. 2e). Accordingly, the frequency of
OPC amongst Tom +, recombined cells increased in Lgl1 cKO,
while the frequency of OL decreased amongst Tom+ cells
(OPC/WT= 62% vs. OPC/cKO= 79%; OL/WT= 33% vs.
OL/cKO= 19%; Fig. 2f). At P120, the frequency of OPC was
still higher amongst Lgl1 cKO Tom+ cells than amongst Lgl1 WT
Tom+ cells (OPC/cKO= 41.3% vs. OPC/WT= 23.4%; p= 0.02)
and the frequency of OL was still lower (cKO= 39.4% vs.
WT= 51.7%; p= 0.02; Supplementary Fig. 2d).
Taken together, these data show that upon Lgl1 knockout,
OL aberrantly retain NG2 protein expression and expand as
OPC marker positive cells, while failing to further differentiate
and mature.
In contrast to postnatal and adult OPC, embryonic OPC are
not committed to the oligodendrocyte lineage and reportedly
also generate astrocytes or neurons9,30,31. To test if Lgl1 deletion
affects the lineage commitment in young adult OPC, we
quantified expression of neuroblast and astrocyte markers
CD24 and GLAST, respectively, by flow cytometry (Supplemen-
tary Figs. 2a, b). As expected, only a small fraction of recombined
cells expressed neuroblast and astrocyte markers (<2%) and the
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Fig. 1 Lgl1 is expressed in oligodendrocyte progenitor cells (OPC) and its expression increases with differentiation into oligodendrocytes. a Scheme of OPC
treatment before qRT-PCR. b Immunofluorescence for OPC marker NG2 and oligodendrocyte differentiation marker O4 of corpus callosum-derived
OPC under proliferating or differentiating conditions. Differentiation increases O4-positive cell frequency. Scale bar= 100 µm. c Graph representing mRNA
expression level changes with differentiation. qRT-PCR results are displayed on a log2 scale and normalized to proliferative conditions. Data represented
as mean ± s.e.m. of five independent experiments (n= 5, *p < 0.05, **p < 0.01, Mann–Whitney test). d, e Co-immunostaining of P35 wildtype mouse
corpus callosum for Lgl1 and OPC marker NG2 (top panels) or differentiation marker CC1 (bottom panels). Insets are high magnification panels of
Lgl1 positive cells (yellow arrows). Scale bar: 100 μm. f Schematic of coronal section of a P60 mouse showing the corpus callosum where cells were
counted. g Quantification of PDGFRα-positive, NG2-positive, and CC1-positive cells per total Lgl1-positive cells. 14% were PDGFRα-positive, 22% were
NG2-positive, and 59% were CC1-positive. Data are represented as mean ± s.e.m. of four independent experiments
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frequency of neuroblasts and astrocytes did not change
significantly following Lgl1 deletion (Supplementary Fig. 2b).
We concluded that Lgl1 loss does not alter the potential of young
adult OPC to generate astrocytes and neuroblasts, suggesting a
specific role of Lgl1 in OL differentiation.
Demyelinating injury increases the rate of OL proliferation and
differentiation when compared with non-lesioned murine
brain32,33. To test if Lgl1 is also required for OL differentiation
in demyelinating lesions, we quantified the frequency of mature
OL marker Plp in lysolecithin-induced lesions in NG2-CreERT2
Ai14-TdTom Lgl1fl/fl and Lgl1wt/wt mice injected with tamoxifen
at P52 (Supplementary Figs. 2e, f). The frequency of Plp-positive
cells amongst recombined cells was significantly decreased upon
Lgl1 deletion (WT= 73.3% vs. cKO= 33.0%; p < 0.01; Supple-
mentary Fig. 2g), showing that Lgl1 is critical for OL differentia-
tion in demyelinating lesions.
Lastly, we tested if the requirement for Lgl1 in differentiation
can be recapitulated ex vivo. To this end, we isolated OPC from
the corpus callosum of GFAP-Cre Lgl1 cKO and GFAP-Cre Lgl1
WT control mice and cultured them under OL differentiation
conditions in vitro34 and stained cells for NG2 and O4.
Quantifications revealed a significant increase of NG2+ cells
and a decrease of O4+ cells amongst all Tom+ cells, upon
Lgl1 knockout (Figs. 2g, h).
Taken together, we conclude that Lgl1 is required for the
downregulation of NG2 and OL differentiation.
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Fig. 2 Lgl1 knockout blocks OPC to OL differentiation. a Schematic of approach for clonal labeling and NG2 Cre-conditional deletion of Lgl1 in OPC.
b Representative triple immunostaining of corpus callosum of Lgl1 WT and Lgl1 cKO from mice treated as in (a) for red fluorescent protein (Tom), OPC
marker NG2 and differentiation marker CC1. Green arrows point to Tom+CC1+ oligodendrocytes. Orange arrows in the Lgl1 cKO panel point to Tom+NG2
+CC1+ cells. Scale bar: 50 µm. c Quantification of NG2+, CC1+, and NG2+CC1+ cells ratios amongst Tom+ cells. Data are represented as mean ± s.e.m.
from the analyses of 4 Lgl1 WT vs. 4 Lgl1 cKO treated mice (**p < 0.01, Mann–Whitney test). d Schematic of broad deletion of Lgl1 in P30 mice followed by
FACS at P60. e Plot showing quantification of OPC (white) and OL (gray) in mice treated following scheme in (d). Data are represented as box & whiskers
± s.e.m. from the analyses of 6 Lgl1 WT vs. 5 Lgl1 cKO treated mice (**p < 0.01, Mann–Whitney test). f Pie charts of quantification for NG2+, O4+,
astrocyte marker GLAST+ and neuroblast marker CD24+ cells amongst Tom+ cells, after Lgl1 knockout at P60 (see also Supplementary Fig. 2b). Data are
represented as percentages from the analyses of 6 Lgl1 WT vs. 5 Lgl1 cKO mice (OPC p < 0.01; OL p < 0.01). g Representative immunostaining for NG2 and
O4 of OPC and OL isolated from GFAP-Cre, Tom, Lgl1wt/wt and, GFAP-CreERT2, Tom, Lgl1fl/fl mice. Scale bars: 100 µm. h Quantification of NG2 and O4 cells
amongst all red fluorescent protein (Tom) positive cells show that Lgl1 knockout strongly blocks the differentiation of OPC into O4+OL. Data are
represented as mean ± s.e.m. from the independent analyses of 4 Lgl1 WT vs. 4 Lgl1 cKO mice (**p < 0.01, Mann–Whitney test)
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Lgl1 is required for asymmetric OPC divisions. Postnatal and
adult OPC divide asymmetrically to generate at a one-to-one ratio
an NG2+ OPC and a CC1+ OL2,3,10. Given that Lgl1 knockout
reduces the number of CC1+ cells (Fig. 2c), we hypothesize that
Lgl1 regulates ACD. To test this hypothesis, we visualized
and quantified ACD in Lgl1 NG2-CreERT2 Ai14-TdTom Lgl1fl/fl
and Lgl1wt/wt mice that were injected with tamoxifen once at
postnatal day 30 (P30) for clonal recombination35. To monitor
proliferation, mice were treated with EdU for 14 days (Fig. 3a),
and cell pairs were identified by co-immunostaining for Tom,
CC1, and EdU2,3 (Fig. 3b). Cell pairs in the corpus callosum were
scored as (i) symmetric, self-renewing (both cells= CC1 nega-
tive), (ii) asymmetric (one CC1-positive and one CC1-negative
cell) and as (iii) symmetric differentiating (both cells= CC1
positive; Fig. 3b). The average cell cycle length of OPC increases
from ~3 days in P20 to 9 days in P60 animals1. Assuming a linear
increase in cell cycle lengths between P30 and P45, recombined
OPC should have divided two to three times during this
period. Indeed, we were able to detect recombined cell pairs at
P45. Amongst these, ACD rates were reduced in the Lgl1 cKO
(WT= 23.2% vs. cKO= 12.5%; p= 0.023). Vice versa, sym-
metric, self-renewing divisions were increased in the Lgl1 cKO
(WT= 28.4% vs. cKO= 51.2%; p= 0.028). Noteworthy, sym-
metric differentiated (CC1+) cell pair rates were not significantly
changed upon Lgl1 cKO (WT= 48.4% vs. cKO= 36%; p= 0.2)
(Fig. 3c and Supplementary Table 1).
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(n= 6, *p < 0.05, Mann–Whitney test)
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Similarly, cell pairs in lysolecithin-induced demyelinating
lesions in the corpus callosum and spinal cord, showed increased
rates of symmetric self-renewing divisions at the expense of ACD
upon Lgl1 knockout (Fig. 3d and Supplementary Figs. 3a, b and
Supplementary Table 1).
To test for a disruption of ACD ex vivo, we generated
Lgl1 KO and Lgl1 WT control OPC and plated them for
pair assays, as described (Fig. 3e)2. We found that the
frequency of ACD was reduced in Lgl1 KO OPC (WT= 72%
vs. cKO= 49%) (Fig. 3f; p= 0.05).
These data show that Lgl1 does not prevent CC1 expression,
but rather prevents downregulation of OPC marker NG2,
thereby lowering rates of asymmetric distribution of NG2.
Thus, Lgl1 is required for ACD and restricts symmetric, self-
renewing divisions in the healthy and injured brain and in the
injured spinal cord.
Lgl1 knockout increases OPC proliferation and promotes
gliomagenesis. Given that Lgl1 knockout cells fail to restrict
expression of pro-mitotic NG2, we hypothesize that their pro-
liferation rates might be increased. We therefore assessed pro-
liferation in NG2-CreERT2 Ai14-TdTom Lgl1fl/fl and Lgl1wt/wt
mice injected with tamoxifen at P30 and exposed to EdU at P45
(Supplementary Figs. 4a–c) and at P60 (Figs. 4a, b and Supple-
mentary Figs. 4d–f). Quantifications revealed that the overall per-
centage of Tom+ cells at P60 was significantly increased in the Lgl1
cKO (14.8%) vs. the Lgl1 WT corpus callosum (7.9%; p= 0.0005;
Fig. 4a, b). Moreover, we chemically labeled EdU-positive (Edu+)
cells. Edu+ cells were 2.3-fold more frequent amongst the Tom+
cells in Lgl1 cKO vs. the Lgl1 WT corpus callosum (p= 0.014;
Supplementary Figs. 4b, c) at P45. A similar increase was observed
in demyelinated corpus callosum of P55 mice (1.8-fold higher
EdU+ cells amongst Tom+ Lgl1 cKO vs. Lgl1 WT; p= 0.007)
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05099-3
6 NATURE COMMUNICATIONS |  (2018) 9:2862 | DOI: 10.1038/s41467-018-05099-3 | www.nature.com/naturecommunications
(Supplementary Figs. 4d–f). These data indicate that Lgl1 restricts
proliferation of OPC in the healthy and demyelinated CC.
Increased proliferation, defective differentiation, and decreased
rates of ACD are associated with gliomagenesis2. We therefore
tested whether Lgl1 knockout promotes tumor formation. Immu-
nostainings of normal adult mouse brain revealed that OL express
the tumor suppressor p19Arf (Supplementary Fig. 5a)36. We
therefore bred Lgl1 floxed mice21 with a NG2-Cre driver line37,
and mice heterozygous for the Ink4a/Arf deletion (Ink4a/Arf+/−)
38. Mice were monitored for neurological signs of tumor formation
and survival. We observed that 100% of Lgl1 WT Ink4a/Arf+/−
mice were still alive at 60 weeks postnatal age, whereas Lgl1 cKO
Ink4a/Arf+/− mice had a significantly shorter median survival of
45.79 weeks (Fig. 4c; p= 0.0108). Histopathologic analyses of Lgl1
cKO Ink4a/Arf+/− brains showed infiltrative tumors consistent
with astrocytoma morphology (Fig. 4d). Expression analysis by qrt-
PCR in tumor cells isolates showed a strong reduction of p19Arf
mRNA versus Lgl1 cKO Ink4a/Arf WT and Ink4a/Arf+/− cells,
suggesting that the WT allele of p19Arf is not expressed in the tumor
(Supplementary Fig. 5b). Fluorescent immunostainings of brain
sections from tumor-bearing mice showed that tumors express the
oligodendrocyte lineage and glioma markers Olig2 and NG2.
Results are indicative of a mixed astrocytic and oligodendroglial
high-grade glioma (Figs. 4d–f)39.
To determine whether our animal model findings were
clinically relevant, we mined expression data from 99 patients
from The Cancer Genome Atlas (TCGA) for a potential
association of Lgl1 mRNA expression levels and glioblastoma
patient survival. We found that low levels of Lgl1 mRNA
expression correlated with poor patient survival (Supplementary
Fig. 5c)40. In further support of a tumor suppressive function,
Lgl1 protein expression was absent in six out of seven human
glioblastoma xenografts as shown by immunoblotting (Supple-
mentary Fig. 5d). Collectively, these data showed that Lgl1
attenuates OPC proliferation and synergizes with tumor sup-
pressor Ink4a/Arf to suppress gliomagenesis.
Lgl1 cKO OPC show a defect in NG2 routing to the lysosome.
A recent study showed that levels of surface NG2 are regulated by
endocytosis15. We hypothesize that Lgl1 cKO OPC fail to
route NG2 to the lysosome and thereby sustain aberrantly high
NG2 levels. In order to test this, we transfected Lgl1 cKO and
WT cells with lysotracker GFP (Lys-GFP) and labeled cell
surface NG2 with an antibody specific for its extracellular domain
(NG2-EC) and a fluorescent secondary antibody. Cells were
consecutively monitored by fluorescent time-lapse microscopy
for up to three hours under differentiation conditions. In both
Lgl1 cKO and WT OPC, NG2-EC started to reach the lysosome
one hour post imaging (Fig. 5a). Co-localization of NG2-EC with
Lys-GFP peaked in Lgl1 WT cells three hours after starting
the imaging. Interestingly, we observed a significantly higher
colocalization of NG2 with lysosomes in WT OPC compared to
Lgl1 cKO OPC (WT= 79.6%; cKO= 54.7%, p= 0.0047) (Fig. 5a)
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suggesting that in differentiating OPC, Lgl1 acts as a positive
regulator of NG2 trafficking to the lysosome. These results
prompted us to stain for the lysosome associated membrane
protein 1 (Lamp1) to investigate whether the lysosome is formed
properly in Lgl1 knockout cells. We find that lysosomes are
present in Lgl1 cKO OPC, based on Lamp1 positivity and sub-
cellular localization. Noteworthy, lysosome shape appears to be
altered due to Lgl1 knockout (Fig. 5c). Collectively, these results
show that Lgl1 positively regulates NG2 trafficking to the
lysosome.
Non-degraded NG2 in Lgl1 cKO OPC is recycled to the
membrane. Given that NG2 is a transmembrane proteoglycan41,
we suggest that it might be recycled to the membrane by the
recycling endosome, a tubular structure continuous with the early
endosome. To test this, we incubated Lgl1 cKO cells in differ-
entiating conditions and live labeled NG2-EC. Cells were fixed
at different time points after surface NG2 labeling and stained for
recycling protein markers. At 45 min, we observed a higher
colocalization of NG2-EC with the recycling regulator Rab11 in
Lgl1 cKO compared to WT cells (Fig. 6a). At 24 h, NG2-EC
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colocalizes with ARF6, a GTPase critical for endocytic recycling,
supporting the notion that NG2 is recycled to the membrane in
Lgl1 cKO OPC (Fig. 6b). Additionally, NG2-EC overlaps with
Rab4, a GTPase marker for fast endocytic recycling, hinting that
NG2 recycling may not be restricted to the slow recycling path-
way (Fig. 6c). We also observed co-localization of NG2-EC with
the early endosome marker EEA1 (Fig. 6d), suggesting that NG2
is constantly uptaken and shuffled back to the membrane.
Noteworthy, we observed a coexpression of Lgl1 and the early
endosome-specific protein Rab10 both at the membrane and
around the nucleus, further associating Lgl1 role with the endo-
cytic machinery42 (Supplementary Fig. 6).
In order to better investigate a potential NG2 recycling in Lgl1
cKO cells, we used total internal reflection fluorescence (TIRF) to
monitor live-labeled NG2-EC docking to the membrane. Cells were
plated in differentiation medium for four hours and then monitored.
By this time, the majority of NG2 is degraded in Lgl1 WT cells and
no significant NG2 recycling was observed (Fig. 6e,). To the contrary,
NG2-EC was more abundant and continuously re-introduced to the
membrane in Lgl1 cKO OPC (Figs. 6f, g; Supplementary Movie 1
see Methods).
Collectively, these data proof that in Lgl1 cKO cells, NG2 is
mostly recycled to the membrane rather than degraded.
Lgl1 cKO OPC show premature and accelerated endocytosis
recycling of NG2. To better characterize the deregulation of
endocytosis in Lgl1 knockout cells, we acutely isolated Tom+
cells from Lgl1 NG2-CreERT2 Ai14-TdTom Lgl1fl/fl and Lgl1wt/wt
control mice injected with tamoxifen at P30. Fifteen days after
starting Lgl1 knockout, gene expression was analyzed using high-
sensitivity, whole-transcript arrays (Fig. 7a; see also Methods). By
analyzing the 318 genes differentially expressed between Lgl1 WT
and Lgl1 cKO OPC (p < 0.05), ingenuity pathway analysis iden-
tified several pathways including the receptor-mediated endocy-
tosis pathway to be upregulated in Lgl1 cKO cells (Fig. 7b;
activation z-score= 2, p= 0.018). Upregulation of early endocy-
tosis genes Ap2a1, Ep41I2, Hip1R, EEa1, Reps1, Syne1, and Pdl1
was further validated by qrt-PCR in Lgl1 cKO OPC vs. Lgl1 WT
OPC (Fig. 7c). These data suggest that Lgl1 knockout deregulates
endocytic uptake in addition to endocytic recycling.
In order to investigate if early endocytosis is affected in Lgl1
cKO cells, we labeled surface NG2 with the NG2-EC antibody,
and marked the early endosome by expression of Rab5a-GFP.
Time-lapse imaging of cells for 30 min in differentiation
conditions showed a prominent colocalization of NG2 with
Rab5a only in mutant cells, suggesting that Lgl1 negatively
regulates NG2 uptake (Fig. 7d). We corroborated these results by
quantifying the endocytosis of transferrin using FACS, and found
a ten-fold increase in transferrin incorporation in Lgl1 cKO OPC
as compared to Lgl1 WT OPC (Supplementary Fig. 7).
Next, we tested whether NG2 is only recycled after failing to
be degraded or also when prematurely internalized in Lgl1 cKO
OPC. We used TIRF to monitor labeled NG2 docking to the
membrane over the first 5 min of differentiation conditions. We
observed that a significantly higher ratio of labeled NG2 was
endocytosed and recycled to the membrane in Lgl1 cKO cells
compared to WT cells (WT= 15%; cKO= 58%, p < 0.0001)
(Figs. 7e–g). Taken together, these data show that Lgl1
negatively regulates NG2 internalization and recycling and
establish Lgl1 as a regulator of NG2 trafficking by the endocytic
pathway.
Differentiation defect in Lgl1 cKO OPC is linked to aberrant
NG2 recycling. Our studies above suggest that Lgl1 knockout
enhances NG2 internalization and recycling to the membrane,
thereby preventing NG2 degradation and blocking OL differ-
entiation. In order to dissect whether abnormal NG2 recycling
has an effect on OL differentiation, Lgl1 cKO cells were incubated
for 4 hours with monensin (10 μM), a drug widely used to
interrupt protein recycling43. We tested if the drug has a specific
effect on NG2 recycling in Lgl1 cKO cells by monitoring Tom+
cells under TIRF for up to one hour after monensin treatment.
We observed that monensin treatment blocked NG2 recycling,
validating the reported drug effect on recycling (Fig. 8a)43. Lastly,
we assessed differentiation in treated and non-treated Lgl1 cKO
cells kept in differentiation conditions for 5 days by O4 and NG2
co-immunostaining. A quantification of marker-positive cells
showed that monensin treatment significantly increased the ratio
of O4+ cells at the expense of NG2+ cells (treated/O4+= 75%
and NG2+= 24%; non-treated/O4+= 9% and NG2+= 90%;
p < 0.0001) (Figs. 8b, c).
These results link abnormal recycling of surface NG2
and defective OL differentiation.
Discussion
Adult OPC differentiate in multiple steps, beginning by commit-
ting to OL fate and ending by maturing and producing myelin.
There is a wealth of studies on the later steps of OL differentiation
and maturation34,44. Little is known, however, about the earliest
decisions between OPC and OL fate. Thus far, the down-
regulation of proteoglycan NG2 is the earliest immunophenotypic
change that distinguishes the two daughter cells within a newly
formed OPC pair upon ACD. NG2 marks the OPC daughter,
while the NG2-negative daughter acquires CC1 expression, which
marks OL differentiation2,3,9. NG2 knockout OPC show delayed
proliferation, which indicates that NG2 controls the timing of
OPC proliferation7 (reviewed by Sakry et al.45). The NG2
knockout does not fully block OPC proliferation and differentia-
tion and its effect is only temporary7. Thus, downregulation of
NG2 is an important but not the only step for OL commitment.
Indeed, PDGFRα is also asymmetrically distributed amongst
newly formed OPC pairs3, further suggesting that cell fate deter-
minants in addition to NG2 link ACD to differentiation46.
Due to the reported functional, morphologic, and neuroana-
tomical heterogeneity of OPC47, and its potential influence on cell
division mode, cell cycle lengths, and differentiation1,9,48,49, we
focused our studies on OPC in the corpus callosum. We analyzed
OPC in mice between the ages P30 and P60 with the exception of
tumor-bearing mice, which were older. The rationale for ana-
lyzing OPC at these stages was that the analyses of mice older
than P60 would be technically very difficult due to a long OPC
cell cycle time1. We expect to detect the maximum number of
ACD between P30 and P60, because the rates of asymmetric OPC
divisions are already high at postnatal stages (P20; ACD= ~35%)
and peak at P60 (ACD= ~45%) before decreasing again with age
(P120; ACD= ~35%)3. Moreover, the rate of differentiation
remains stable at 40% between P30 and P609, which makes is a
suitable range to identify potential effects on differentiation of a
single gene knockout.
Since ACD generate differentiated cells from stem and pro-
genitor cells across species, it was attractive to speculate that
conserved regulators of ACD, such as Lgl1, regulate early steps in
OL differentiation. Previous studies showed that Lgl1 localizes to
the lateral membranes and cytoplasm of embryonic neural pro-
genitor cells21,22. Expression of Lgl1 protein in rat neocortex
homogenates persists into adulthood42. Functional analyses in the
adult brain, however, were limited to its role in SVZ neural stem
cells, neurons, and astrocytes21–23,42.
Here, we show that Lgl1 cKO cells fail to lose NG2 expression
and exhibit differentiation defects. Interestingly, we find that Lgl1
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knockout in OPC increases the rates of cells in a transitional state
and expressing both OPC marker NG2 and OL marker CC1, at
the expense of mature OL. These data indicated that Lgl1 loss
does not prevent the expression of CC1 but rather prevents
downregulation of NG2, and thereby permanently attenuates
differentiation.
Whereas normal OPC populate the brain sparsely and show
little overlap in the areas that two adjacent OPCs occupy50, they
are denser in demyelinated lesions, such as those typically found
in chronic inflammation models in mice and in multiple sclerosis
patients32,33. We found that Lgl1 is a critical regulator of OL
differentiation during remyelination following chemical-induced
demyelination. OPC are considered a critical source for remye-
lination and failed OPC differentiation are thought to be one
important underlying cause for failed remyelination in chroni-
cally demyelinated lesions51. It is interesting to speculate that
Lgl1 functions at an early step in the complex regulatory process
of remyelination and thus may be a viable target for approaches
aimed at promoting proper differentiation of OPCs in demyeli-
nated lesions.
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Our analyses of cell division modes support the hypothesis that
Lgl1 restricts NG2 during ACD as part of the mechanism to turn
on OL differentiation in the NG2-negative progeny. Moreover,
Lgl1 does not disrupt symmetric, differentiating divisions, which
suggests that it specifically regulates differentiation in the ACD
progeny. To date, only a few conserved ACD regulators have a
known function in OL differentiation in addition to Lgl1. These
include the polarity regulator partitioning-defective 3 (Par3)
protein, which promotes myelination in the peripheral nervous
system52, and the transcriptional regulator Prox1, which is
required for OL lineage in the mouse. Par3, Prox1, and Lgl1 are in
the same protein network that controls ACD in Drosophila
neuroblasts46. A role for Par3 and Prox1 in ACD of OPC has yet
to be determined.
Multiple studies have shown that OPC13,14 and OL36 are a
cellular origin of glioma in genetically engineered mouse models.
The neoplastic transformation of OPC and OL and formation of
gliomas are associated with increased proliferation, decreased
differentiation, changes in the tumor microenvironment53, and a
decrease in ACD2. Lgl1 knockout during embryonic neurogenesis
disrupts the asymmetric division of neuroepithelial cells and
generates rosette-like structures reminiscent of PNETs but peri-
natal death prevented the analyses of tumor formation21.
Lgl1 knockout in cell types known to only undergo symmetric but
not asymmetric divisions, such as astrocytes, did not generate
premalignant lesions23. Taken together with our data, these
findings suggest that defective ACD might be an underlying cause
for proliferation and differentiation defects in glioma cells. Our
data support the notion previously observed in epithelial cells54
that loss of polarity—albeit by itself not sufficient to induce
carcinogenesis—contributes to tumor formation. We show that
Lgl1 loss synergizes with Ink4a/Arf loss, which is a frequent and
early event in glioma24, to induce gliomagenesis (Fig. 4). There
is strong precedence for Ink4a/Arf heterozygous mice to be as
susceptible as Ink4a/Arf nullizygous mice to gliomagenesis55. A
likely explanation for this is, that the remaining Ink4a/Arf allele
in tumors arising from Ink4a/Arf+/− mice is inactivated at high
frequency, which is supported by our findings that p19Arf mRNA
expression is greatly reduced in Lgl1 KO tumors. Although 19Arf
and p16Ink transcripts are reportedly low in OPC and OL, we find
overlapping expression of the p19Arf protein and OL marker CC1
(Supplementary Fig. 5). This is interesting, because p19Arf but
not p16Ink is an important tumor suppressor in a glioma mouse
model study36. Collectively, the data suggest that tumor forma-
tion in NG2-Cre Lgl1 KO Ink4a/Arf+/− mice required inactiva-
tion of p19Arf expression, hence the long latency (Supplementary
Fig. 5). It is also plausible that Lgl1 suppresses tumor formation
by restricting NG2 function as a co-receptor for receptor tyrosine
kinases, since deregulated PDGFRα and EGFR signaling activity
contributes to gliomagenesis40,56 (for review see ref. 57).
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Endocytosis has a range of functions including regulating the
cell surface expression and subcellular localization of proteins,
remodeling the membrane and controlling signaling pathways16.
Studies in Drosophila epithelia cells support a link of polarized
protein localization and endocytosis by showing that loss-of-
function mutants of the critical endosome adaptor AP2 leads to
defects in polarity and differentiation similar to those observed
in Lgl loss-of-function experiments58. Our study proposes an
unprecedented link between defects in NG2 endocytic trafficking,
ACD, and differentiation. Indeed, in Lgl1 cKO mutant cells, we
find that NG2 is not properly routed to the lysosome and instead
is recycled to the membrane. These observations show that
endocytic pathway defects in Lgl1 cKO OPC disturb the regular
intracellular itinerary of NG2 during differentiation and lead to
its recycling rather than degradation. NG2 levels are permanently
suppressed in OL most likely as a result of downregulation of
the NG2 promoter in the OL daughter after ACD3.
Taken together, these data suggest that the unequal distribution
of NG2 in the newly formed progeny of ACD is achieved by NG2
degradation in the lysosome and is maintained by silencing the
NG2 promoter in the OL daughter.
We can only speculate as to whether Lgl1 regulates NG2
trafficking directly or, indirectly, by regulating the endocytic
machinery. Although not previously implicated as a negative
regulator of endocytosis in mammalian cells, Lgl1 activates
endocytosis protein and GTPase Rab10 by releasing the GDP
dissociation inhibitor (GDI) in rat hippocampus to induce
polarized axon growth42. In cells undergoing ACD, such as
Drosophila neuroblasts, Lgl1 establishes cell polarity by
mechanisms that regulate myosin II activity, directed vesicle
transport and the subcellular localization of proteins (for review
see ref. 46). Nonmuscle myosin II (NMII) is a critical regulator
of clathrin-mediated endocytosis59 and is a negative regulator of
oligodendrocyte morphological differentiation60. Lgl1 associates
with NMII and inhibits filament formation61 and reduces the
association of NMII with actin. Whether Lgl1 regulates endocy-
tosis by affecting motor protein dynamics or through other
mechanisms, such as regulating the subcellular localization of the
GTPases62,63, remains to be determined. In further support of an
indirect effect of Lgl1 on endocytic trafficking, Drosophila Lgl1
regulates vesicle acidification in the lysosome64,65. Noteworthy,
our data indicate that lysosomes in Lgl1 cKO OPC have a tubular
shape rather than the vesicular shape seen in WT OPC, hinting
that lysosome maturation might be affected by Lgl1 knockout
(Fig. 5).
Future studies should investigate further the potential link of
defects in endocytosis and gliomagenesis.
Methods
Mice. All mouse experiments were approved by and performed according to the
guidelines of the Institutional Animal Care and Use Committee of the University of
California, San Francisco. Lgl1lox/lox mice were courtesy of Dr. Vasioukhin21 and
were bred with NG2-Cre (Jax strain 008533)37 and GFAP-Cre (Jax strain 004600)66,
NG2-CreERTM (Jax strain 008583)9 and Ai14 Cre reporter mice (Jax strain 007908)
29 mice or Ink4a/Arf hemizygous knockout mice38. Ascl1GFP67 and NG2DsRed37
mice from Jackson Laboratories were bred together to obtain Ascl1GFP-NG2DsRed
double transgenic mice. FVB/N mice were obtained from Simonsen Laboratories,
Gilroy. For survival studies, Lgl1 cre-conditional deleted mice were kept under
observation until reaching the major endpoint, which was animal neurological
symptom-free survival.
Induction of Lgl1 knockout and demyelination. Tamoxifen (Sigma-Aldrich) was
dissolved in corn oil (Sigma-Aldrich) at 20 mg/mL and injected intraperitoneally
(i.p.) at 1 mg to induce Cre activity Lα-lysophosphatidylcholine (lysolecithin=
LPC, Sigma-Aldrich) was dissolved at 1% in physiological serum and 0.5 μl were
injected to induce demyelination. For clonal labeling of NG2 cells P30-P52 NG2-
CreERT2, TdTom, Lgl1fl/fl and NG2-CreERT2, TdTom, Lgl1wt/wt mice were injected
with 1 mg tamoxifen twice within 24 h35. To assess proliferation rates and cell
division modes of OPC, mice were subsequently treated with 0.1 mg/mL EdU in
drinking water for 14 days and resected brains were processed for immuno-
fluorescence. For differentiation NG2-CreERT2, TdTom, Lgl1fl/fl and NG2-CreERT2,
TdTom, Lgl1wt/wt mice were injected with tamoxifen either once or twice daily for 4
consecutive days. Mice were analyzed 30 days post injection.
For broader deletion of Lgl1, P30-P52 NG2-CreERT2, TdTom, Lgl1fl/fl and NG2-
CreERT2, TdTom, Lgl1wt/wt mice were injected with tamoxifen twice daily for 4
consecutive days. FACS isolated OPC were subjected at P45 to microarray analyses.
To assess proliferation and cell division modes in demyelinated lesions,
demyelination was induced by a single LPC injection into the CC or the spinal cord
of mice previously injected with tamoxifen. For differentiation, demyelination was
induced by LPC injection after the last tamoxifen injection and mice were sacrificed
10 days after to evaluate the effect on OPC differentiation. For spinal cord white
matter demyelination, mice were anesthetized with isofluorane and demyelination
was induced by LPC into the ventral or dorsal white matter funiculus at the level of
T1268,69. For CC demyelination, LPC was injected in the right or the left
hemisphere (AP+1 mm, L ± 1 mm, DV-2.1 mm)70. For EdU labeling, mice were
injected i.p. with 10 mg/mL EdU twice a day, or EdU was mixed with drinking
water at a low concentration (0.1 mg/mL) for 5–14 days. For long-term tracking
of Lgl1 deletion effects, tamoxifen was injected at P30 for 5 consecutive days,
and tissue analyzed by FACS at P120.
Cell culture. Cells were isolated from the CC, which includes the subcallosal zone
of P30–P60 mice, and cultured as non-adherent spheres in proliferative medium
with NT3, CNTF, PDGFA, and FGF2 (Peprotech)34. Differentiation was induced
by plating cells on poly-L-Lysine coated glass-bottom 96-well plates (CORNING) at
5000 cells/mL in medium containing CNTF, FGF2, and T32. Cells were incubated
with inhibitor of endocytosis Pitstop1 at 25 μM. To induce Lgl1 deletion in vitro,
cells were incubated with adenovirus-cre-GFP (Vector BioLabs) and adenovirus-
GFP2. Viability assay was performed using the Alamar Blue reagents71.
Pair assay. Cells were subjected to a pair assay by plating dissociated single cells at
clonal density for 12–36 h. Cell pairs formed were fixed and subjected to immu-
nostaining with primary antibody and fluorescence-coupled secondary antibody2.
Nuclei were visualized using DAPI (Sigma). Unless indicated otherwise, for pair
assay a minimum of 50 and up to 200 cell pairs per cell type and condition,
respectively, were analyzed, using a fluorescent microscope.
Immunofluorescence and in vivo cell pair assays. NG2-CreERT2,TdTom, Lgl1fl/fl
and NG2-CreERT2,TdTom, Lgl1wt/wt mice injected with tamoxifen were PFA
perfused, brains were resected and frozen, sectioned and post-fixed for 10 min with
4% PFA, blocked with PBS 5% normal goat serum (NGS) or normal donkey serum
(NDS) and 0.1% Triton X-100 for 1 h. For cell pair assays, sections were stained
for anti-red fluorescence antibody (to detect the NG2+ cells and progeny with
Lgl1 deletion) and anti-CC1 antibody overnight, washed and stained with
fluorescence-couple secondary antibodies. Cell pairs were identified as two red
fluorescence-positive (NG2Tom) and EdU-positive cells spaced less than 20 µm2,3.
The entire CC was counted as three or more distinct brain sections per animal
in 4–5 individual animals per group. Cell pairs with one CC1-positive cell were
scored as an ACD.
The following antibodies were used at the given concentration:
α-Rb NG2 (Millipore 1:200), αMs-IgM O4 (R&D, 1:400), α-Ms CC1
(Calbiochem, 1:100), α-Gt Dcx (Santa Cruz Biotechnology, 1:300), α-Gt Hugl-1
(Lgl1, Santa Cruz biotechnology, 1:200), α-Rb Hugl-1 (Lgl1, Santa Cruz
Biotechnology, 1:200), α-Ms Nestin (Chemicon international, 1:400), α-Rb PlP
(abcam105784, 1:1000), α-Rat MBP (abcam7349, 1:400), α-Rb-beta galactosidase
(ab616, 1:200), gt-α-Olig2 (EMD Millipore; 1:200), α-Rb-Rab11 (Life Technologies
Corporation, 1:200); α-Rb-p19Arf (Santa Cruz; 1:100); α-Gt-Lamp1 (R and D
systems AF4320, 1:100); α-ARF 6 (Santa Cruz sc-7971; 1:200), α-Ms EEA1
(Santa Cruz sc-365652, 1:150); α-Rb-Rab4 (Millipore 07-655; 1:200); α-Ms-Rab10
(Life Technologies Corporation, 1:100).
For O4 staining, cells were stained live in vitro: O4 was incubated 1 h (1:400)
at 37 °C in the corresponding culture medium (OPC proliferation or OL
differentiation) before PFA fixation and further antibody staining.
EdU was visualized using the Click-it reaction kit (Life Technologies
Corporation) following the manufacturer’s instructions71.
Early endocytosis compartment was visualized using the BacMam technology
following manufacturer’s instructions (Life Technologies Corporation).
Immunofluorescent images were acquired on a Nikon Ti-E microscope with Nikon
perfect focus system equipped with a Hamamatsu Flash4.0 camera equipped with
a 40×/0.75 Plan Fluor objective and/or Nikon Ti Yokogawa CSU-22 spinning
disk confocal equipped with a Plan Apo VC 60×/1.4 oil objective. Images were
analyzed with NIS-Elements 4.2 (Build 982) and ImageJ.
FACS. NG2-CreERT2,TdTom, Lgl1wt/wt and, NG2-CreERT2,TdTom, Lgl1fl/fl mice
were analyzed by FACS 30 days or 120 days after tamoxifen injection at P30.
Lateral ventricle walls and/or CC cells were isolated from Ascl1-GFP and NG2-
DsRed double-transgenic mice at P60. For DNA content analysis, dissociated cells
were incubated with the vital DNA marker Hoechst 33342 (Sigma)72. The anti-
bodies to identify distinct cell populations were anti-O4–biotin (MACS Miltenyi
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Biotec; 1:10) conjugated to streptavidin–FITC (MACS Miltenyi Biotec; 1:10);
CD140a phycoerythrin–cyanine7 [PC7]-conjugated (mouse clone APA5; 1:100
eBiosciences); CD24 phycoerythrin–cyanine7 [PC7]-conjugated (Rat IgG2b; 1:100
Life Technologies); CD140b [APC]-conjugated (life technologies clone APB5,
1:50), and Glast-APC (MACS miltenyi, 1:30). Cells were gated following the
fluorescence minus one (FMO) control. For microarray analyses, CC tissue was
isolated from NG2-CreERT2, TdTom, Lgl1fl/fl (n= 4) and NG2-CreERT2, TdTom,
Lgl1wt/wt (n= 5) triple-transgenic, P30 mice injected twice daily with tamoxifen
for 4 consecutive days and OPC were obtained by sorting for Tom-positive,
PDGFRα-positive O4-negative cells.
To perform absolute cell counts, single cell suspensions were transferred to
tubes containing a calibrated number of fluorescent beads (TruCount tubes, BD
Biosciences)73. Prior to FACS sorting propidium iodide (PI) or Hoechst 33258
was added to a final concentration of 2 µg/mL to label the dead cells. Cells were
analyzed and sorted on a FACS ARIA II (BD Biosciences). The data were analyzed
with FlowJo data analysis software (Tree Star, Ashland, OR, USA).
Immunoblotting. Glioblastoma xenografts proteins were extracted using cell lysis
buffer (Cell Signaling) supplemented with proteinase and phosSTOP phosphatase
inhibitor cocktail (Roche). Proteins were separated by SDS-PAGE and transferred
onto polyvinylidene difluoride membranes, which were then probed with primary
antibodies, followed by horseradish peroxidase-conjugated secondary antibody,
and visualized by ECL (GE Healthcare). Antibodies specific for Hugl1 and tubulin
as loading control were from Sigma.
RNA extraction and reverse transcription. For all experiments, RNAs were
extracted with QIAGEN RNeasy microkit and reverse transcribed into cDNAs
using high capacity RNA to cDNA kit (Applied Biosystems).
Taqman low-density arrays. For the Taqman low-density array experiment,
200–500 cells/population were sorted from the CC of young adult Ascl1-GFP and
NG2-DsRed double-transgenic mice. TaqMan® Array Micro Fluidic Card were
designed for neural stem cell, oligodendrocyte progenitor cell and differentiated
oligodendrocyte markers, as well as well selected ACD regulators. A PreAmp
pool was designed for these specific primers and a preamplification reaction was
set up to 14 cycles according to manufacturer’s instructions (Custom TaqMan®
PreAmp Pools Protocol, Applied Biosystems).
Whole-genome microarrays. For the microarray experiments 200–500 Lgl1
knockout and wildtype OPC cells (PDGFRα and red fluorescent protein positive
O4 negative), were extracted with the RNA plus micro kit (QIAGEN) and reverse
transcription into cDNAs was performed using the High Capacity Reverse Tran-
scription Kit (Thermofisher scientific). Sample quality was controlled using the
Agilent Bioanalyzer and samples were loaded on GeneChipR Mouse Gene 2.0 ST
Arrays (Affymetrix). Microarray data were analyzed using Partek® Genomic Suite
6.6 with RMA normalization and differential gene expression detected with
ANOVA. Ingenuity pathway analyses (QIAGEN bioinformatics) were used to
identify targets and pathway differentially expressed between the Lgl1 WT and Lgl1
cKO samples.
Real-time quantitative reverse transcription PCR. Receptor-mediated endocy-
tosis regulator genes were validated by qRT-PCR on OPC cultured from GFAPCre,
dTomfl/fl, Lgl wt (n= 6) vs. Lgl1fl/fl (n= 6) mice using the following primers: Ap2a1
(5′–3′: GGAACCTCCTGGTGGATGTC, 3′–5′: AGGACCTGGGCTGAGGAAG);
Epb41l2 (5′–3′: GCCCCAGTCAGGGAATTTCA, 3′–5′: TTACCGCTTACACC
GGACAC); Hip1r (5′–3′: ATCTGGCCAGGAGCAGATTG, 3′–5′: AAGACTCGC
ACCTGTGTCTC) Eea1 (5′–3′: TCTTCAGAGGGTTTCATATGTCCC, 3′–5′: TG
AGGCCTGTAGGTCTTGGA) Reps1 (5′–3′: GCAGATACTCCACCAACCAGT,
3′–5′: GTACTGTCGTCTGGTCCTGG); Syne1 (5′–3′: GACATGCAGGGAGTCA
CACA, 3′–5′: CTTTTTGCTGCTGGAGGCTG); Pld2 (5′–3′: ATCCT-
GAAGGCTCACGAACAG, 3′–5′: GAAGAAAGGGTGAAGGAGGCA); p19Arf
(Forward: 5′–3′: TGAGGCTAGAGAGGATCTTGAGAAG, Reverse: 5′–3′:
GTGAACGTTGCCCATCATCATC); LLgl1 (exon 2–3 Forward: 5′–3′: CCACAA
GACTGTGGAGCATGG, Reverse: 5′–3′: AAA-TGC-ATC-TGG-GTG-ACG-GT).
Transferrin uptake. The CC of GFAP-Cre, dTomlox/lox, Lgl1 wt/wt(n= 4) vs. Lgl1
ox/lox (n= 4) was extracted from young adult mice (P60). After enzymatic digestion
with papain (10 min, 15 U/mL)72, cells were washed with cold wash solution (PBS
containing 20 mM glucose and 1% BSA). Then Transferrin Alexa Fluor 488 con-
jugate (Molecular probes, T13342)74 was added at 25 µg/mL and incubated at 37 °C
for 15 min. Non-internalized ligand was removed from the cell surface using three
5 min wash with ice-cold freshly prepared stripping buffer (PBS/0.15% BSA, pH 3.5
adjusted with HCL) and washed three times with cold wash solution. Data analysis
to quantify changes in Transferrin fluorescence in dTom+ cells was performed
using a FACS Aria II (BD Biosciences) and analyzed with FlowJo data analysis
software (Tree Star, Ashland, OR, USA).
Live staining of cells. Plated Lgl1 cKO and WT OPC were incubated on ice at 4 °C
for 2 h with α-NG2-EC (Rabbit, courtesy of Dr. Stallcup) in Neurobasal medium
(3% BSA). After two washes with neurobasal medium, cells were incubated for 1 h
with an Alexa488 goat α-Rabbit. For lysosome tracking, cultured OPC were
incubated with CellLight Reagent BacMam 2.0 (Molecular probe) 24 h prior to live
imaging targeting the early endosome Rab5a (C10586) and lysosome-specific
protein Lamp1 (C10507) at a concentration of 50 PPC.
Fluorescence time lapse microscopy. Time lapse movies were taken under a
conventional widefield epifluorescence system (Nikon) equipped with a 37 °C
incubation chamber and CO2 control for live cell imaging. Live-labeled cells
were incubated in differentiation conditions and the system programed to take
fluorescent pictures at the following frequencies: 1 frame/30 s to follow early
NG2 endocytosis and 1 frame/1 h to follow its trafficking towards lysosomes.
TIRF microscopy. Live labeled cells (NG2-EC) were plated in differentiation
conditions and placed on a coupled incubator for live cell imaging (37 °C, 5% CO2)
under the TIRF microscope. Fluorescent pictures were taken at different
frequencies: 1 frame/30 min or 1 frame/30 s. TIRF was used to provide a mean to
selectively excite fluorophore very near the solid surface (<100 nm) without
exciting fluorescence from regions farther from the surface. Therefore, any
Alexa488 positive dot in perfect focus was considered as a docking NG2 on the
membrane region that is being imaged. Different quantities of NG2 recycling over
time were represented as total corrected fluorescence measured using ImageJ.
Recycling inhibition. Lgl1 cKO OPC were treated with differentiation medium
containing 10 μM Monensin (TOCRIS, 5223) for 4 h. Cells were monitored
under TIRF for NG2 recycling monitoring during the first hour of treatment or
were switched back to normal differentiation medium for 5 days before being
fixed and immunostained for O4 and NG2. Endocytosis of the proteoglycan NG2
was followed using a mouse-anti-NG2.EC antibody against the extracellular
domain of NG2 (courtesy of Dr. Stallcup). OPC cultures were incubated 24 h prior
to live imaging with CellLight® Reagents BacMam 2.0 (Molecular Probes) targeting
the early endosome-specific protein Rab5a (ref C10586) of lysosome-specific
protein Lamp1 (ref C10507) at a concentration of 50 PPC. Cells were starved 2 h
prior to imaging in NBA medium, and 50 ng/mL of PDGF-AA was added right
before imaging to induce endocytosis. Time-lapse movies were taken over time
spans of 30–45 min with 30 s interval between the images to follow early endo-
cytosis of NG2 antibody and 2–3 h with a 30 min interval to follow its inter-
nalization to the lysosome. After live imaging, cells were fixed 10 min in PFA4%,
stained with the appropriate antibodies and imaged with a Nikon Ti Yokogawa
CSU-22 spinning disk confocal equipped with a Plan Apo VC 60×/1.4 oil objective.
Endocytosis inhibitor. Monensin (TOCRIS, 5223), a selective recycling endocy-
tosis75, was used and was not toxic at a working concentration of 10 µM.
Univariate Cox model. The prognostic significance of high Lgl1 expression
(≥median) on overall survival (defined as the time between diagnosis and death due
to any cause) was retrospectively tested. The follow-up period ranged from 0 to 8
years (median= 1 year). The number of events that occurred during this period
and the number of censored individuals are: 86 events, with 13 censored.
Statistics and analysis. Statistical analyses were conducted as indicated in the
figure legends using GraphPad Prism 5.0 and Microsoft Excel. A Mann and
Whitney two-tailed paired t-test was conducted to analyze for significant differ-
ences between two treatment groups. For Kaplan–Meier survival rate analyses, the
number of surviving mice were recorded daily. The data were subjected to Log-
rank test in order to determine if significant differences existed in survival between
the Lgl1 knockout and control groups. For statistical tests *p < 0.05,**p < 0.01,***p
< 0.001. A univariate Cox models was fitted on the survival data of the 99 glioma
patients (92 GBM and 7 LGG) to obtain p-values. R-function ‘survfit’ (package
‘survival’) was used to generate survival curves from the previously fitted Cox
model.
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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